{"component": "definition", "props": {"groups": [{"snippet": "means Zymeworks\u2019 proprietary Azymetric\u2122 [\u2026***\u2026] technology platform, comprised of mutations which enable the efficient formation of [\u2026***\u2026], as described in the Technical Dossier.", "snippet_links": [{"key": "technology-platform", "type": "definition", "offset": [48, 67]}, {"key": "comprised-of", "type": "clause", "offset": [69, 81]}, {"key": "formation-of", "type": "clause", "offset": [119, 131]}, {"key": "technical-dossier", "type": "definition", "offset": [161, 178]}], "samples": [{"hash": "cnHISgtsnou", "uri": "/contracts/cnHISgtsnou#zymeworks-platform", "label": "Platform Technology Transfer and License Agreement", "score": 31.340862423, "published": true}, {"hash": "18jSgCdp6xa", "uri": "/contracts/18jSgCdp6xa#zymeworks-platform", "label": "Platform Technology Transfer and License Agreement (Zymeworks Inc.)", "score": 28.2525667351, "published": true}, {"hash": "5HH2Q2snB0U", "uri": "/contracts/5HH2Q2snB0U#zymeworks-platform", "label": "Platform Technology Transfer and License Agreement (Zymeworks Inc.)", "score": 28.2142368241, "published": true}], "size": 7, "hash": "6581b4f6f17595ca5d838a57bfbf1b02", "id": 1}, {"snippet": "means Zymeworks\u2019 proprietary Azymetric\u2122 platform.", "snippet_links": [], "samples": [{"hash": "aFgLex9wdfJ", "uri": "/contracts/aFgLex9wdfJ#zymeworks-platform", "label": "License and Collaboration Agreement (Zymeworks Inc.)", "score": 34.3689253936, "published": true}, {"hash": "67KVLz1sOlJ", "uri": "/contracts/67KVLz1sOlJ#zymeworks-platform", "label": "License and Collaboration Agreement (Zymeworks Inc.)", "score": 34.1772758385, "published": true}, {"hash": "bMHayD2qCbX", "uri": "/contracts/bMHayD2qCbX#zymeworks-platform", "label": "License and Collaboration Agreement (Jazz Pharmaceuticals PLC)", "score": 33.9253935661, "published": true}], "size": 6, "hash": "01186bd8e6251cd405e638c94f42a480", "id": 2}, {"snippet": "means Zymeworks\u2019 proprietary antibody engineering tools and capabilities and the amino acid mutations and modifications used to generate 1) antibodies consisting of [\u2026***\u2026] and/or [\u2026***\u2026], and 2) [\u2026***\u2026]. This platform was developed using the Company\u2019s proprietary molecular simulation software suite, known as ZymeCAD\u2122.", "snippet_links": [{"key": "engineering-tools", "type": "clause", "offset": [38, 55]}, {"key": "amino-acid", "type": "clause", "offset": [81, 91]}, {"key": "to-generate", "type": "definition", "offset": [125, 136]}, {"key": "the-company", "type": "definition", "offset": [239, 250]}, {"key": "simulation-software", "type": "definition", "offset": [275, 294]}], "samples": [{"hash": "hKKB6mKk0Qz", "uri": "/contracts/hKKB6mKk0Qz#zymeworks-platform", "label": "Licensing and Collaboration Agreement (Zymeworks Inc.)", "score": 28.2908966461, "published": true}, {"hash": "8d7vYYiDLFw", "uri": "/contracts/8d7vYYiDLFw#zymeworks-platform", "label": "Licensing and Collaboration Agreement (Zymeworks Inc.)", "score": 28.2525667351, "published": true}, {"hash": "3y3Rbfney38", "uri": "/contracts/3y3Rbfney38#zymeworks-platform", "label": "Licensing and Collaboration Agreement (Zymeworks Inc.)", "score": 28.2142368241, "published": true}], "size": 5, "hash": "34043fe50ecee40c69860a6f724f9bd3", "id": 3}, {"snippet": "means Zymeworks\u2019 proprietary Azymetric\u2122 platform or Zymeworks\u2019 proprietary Zymelink\u2122 platform.", "snippet_links": [], "samples": [{"hash": "7ALGu0d0QWd", "uri": "/contracts/7ALGu0d0QWd#zymeworks-platform", "label": "License and Collaboration Agreement (Zymeworks Inc.)", "score": 27.9281314168, "published": true}, {"hash": "gNMcVDFmP1v", "uri": "https://zymeworks.gcs-web.com/static-files/a1aa2254-9dbd-4035-acde-12b459c7e488", "label": "zymeworks.gcs-web.com", "score": 20.378755317, "published": false}, {"hash": "XyCONnJS5k", "uri": "https://ir.zymeworks.com/static-files/a1aa2254-9dbd-4035-acde-12b459c7e488", "label": "ir.zymeworks.com", "score": 10.0650239562, "published": false}], "size": 3, "hash": "550ef46cebde1004be236d3a56bb309b", "id": 4}, {"snippet": "means Zymeworks\u2019 proprietary [\u2026***\u2026], alone or in conjunction with Zymeworks\u2019 proprietary EFECT\u2122 [\u2026***\u2026] platform.", "snippet_links": [], "samples": [{"hash": "5PZYoNse4vh", "uri": "/contracts/5PZYoNse4vh#zymeworks-platform", "label": "Collaboration and Cross License Agreement (Zymeworks Inc.)", "score": 28.2525667351, "published": true}, {"hash": "eKByFnZbzVs", "uri": "/contracts/eKByFnZbzVs#zymeworks-platform", "label": "Collaboration and Cross License Agreement (Zymeworks Inc.)", "score": 26.2142368241, "published": true}], "size": 3, "hash": "54bee7a24b49fb9263bc7b5a017df160", "id": 5}, {"snippet": "means Zymeworks\u2019 proprietary Azymetric\u2122 Fc/Fab heterodimerization platform, alone or in conjunction with Zymeworks\u2019 proprietary EFECT\u2122 effector knock-out platform that is covered by Know-How listed in Exhibit A and patents listed in Exhibit E.", "snippet_links": [{"key": "covered-by", "type": "definition", "offset": [171, 181]}, {"key": "exhibit-a", "type": "clause", "offset": [201, 210]}], "samples": [{"hash": "hMDQZwLbq4M", "uri": "https://www.sec.gov/Archives/edgar/data/1403752/000114420417060772/tv480196_ex99-1.htm", "label": "Collaboration and License Agreement (Zymeworks Inc.)", "score": 14.8959616701, "published": false}, {"hash": "2IhsaW31Syz", "uri": "https://ir.zymeworks.com/static-files/a35f850c-5791-4a0a-ac66-08cf7459ee4b", "label": "ir.zymeworks.com", "score": 10.0184804928, "published": false}], "size": 2, "hash": "b6bba35fdd23e4f5e3e4ef5e5375d842", "id": 6}, {"snippet": "means (a) the Linker-Cytotoxins and (b) any methods for conjugating a Linker-Cytotoxin to a peptide, protein or antibody that are claimed in (i) the Zymeworks Patent Rights listed in Exhibit 1.72, as may be amended from time to time by Zymeworks, or (ii) any patent or patent application claiming priority to such Zymeworks Patent Rights.", "snippet_links": [{"key": "zymeworks-patent-rights", "type": "clause", "offset": [149, 172]}, {"key": "from-time-to-time", "type": "clause", "offset": [215, 232]}, {"key": "patent-application", "type": "clause", "offset": [269, 287]}, {"key": "claiming-priority", "type": "clause", "offset": [288, 305]}], "samples": [{"hash": "488xtaRGQmO", "uri": "/contracts/488xtaRGQmO#zymeworks-platform", "label": "Option and License Agreement (Atreca, Inc.)", "score": 33.5995893224, "published": true}, {"hash": "bVv4ijE02yI", "uri": "https://ir.atreca.com/static-files/4bd19fa7-e75b-4489-b08f-bc1d25ba01b9", "label": "ir.atreca.com", "score": 11.3258042437, "published": false}], "size": 2, "hash": "66c44cb551569901db6871f914103c3d", "id": 7}, {"snippet": "means any or all of (a) Zymeworks\u2019 proprietary Azymetric\u2122 [...***...] heterodimerization platform, (b) Zymeworks\u2019 proprietary EFECT\u2122 [...***...] platform, and (c) Zymeworks\u2019 other proprietary antibody discovery and development capabilities, alone or in conjunction with each other. 27", "snippet_links": [{"key": "discovery-and-development", "type": "clause", "offset": [201, 226]}], "samples": [{"hash": "lrZPHYYmYB3", "uri": "/contracts/lrZPHYYmYB3#zymeworks-platform", "label": "Research and License Agreement (Zymeworks Inc.)", "score": 29.8158795346, "published": true}, {"hash": "4xiiMHiFCQO", "uri": "https://ir.zymeworks.com/static-files/8861b819-3395-48ac-88c7-4230d82bb2c6", "label": "ir.zymeworks.com", "score": 10.0143737166, "published": false}], "size": 2, "hash": "08985da02660083189b8e3684ec4c63e", "id": 8}, {"snippet": "means Zymeworks\u2019 Predictive Protein Engineering Platform which is more fully described in Attachment 1.71. The Zymeworks Platform combines proprietary molecular simulation software with high-performance computing, creating a comprehensive environment for predictive protein engineering and design. The Zymeworks Platform enables the systematic research and design of [\u2026***\u2026], which may be incorporated into antibodies resulting in a protein optimized for a specific need.", "snippet_links": [{"key": "simulation-software", "type": "definition", "offset": [161, 180]}, {"key": "engineering-and-design", "type": "clause", "offset": [274, 296]}, {"key": "research-and-design", "type": "clause", "offset": [344, 363]}], "samples": [{"hash": "2SEqGKwRQEa", "uri": "/contracts/2SEqGKwRQEa#zymeworks-platform", "label": "Research and License Agreement (Zymeworks Inc.)", "score": 28.2525667351, "published": true}, {"hash": "jkX6gFo5uvs", "uri": "/contracts/jkX6gFo5uvs#zymeworks-platform", "label": "Research and License Agreement (Zymeworks Inc.)", "score": 28.2142368241, "published": true}], "size": 2, "hash": "c2adca436930c341daa1d3b519c4c389", "id": 9}, {"snippet": "means Zymeworks\u2019 proprietary [\u2026***\u2026], alone or in conjunction with Zymeworks\u2019 proprietary EFECT\u2122 [\u2026***\u2026] platform.20", "snippet_links": [], "samples": [{"hash": "3QDfis4bHem", "uri": "https://www.sec.gov/Archives/edgar/data/1403752/000119312518167931/d591104dex991.htm", "label": "License Agreement (Zymeworks Inc.)", "score": 17.3750855578, "published": false}, {"hash": "iXgrgwT5p7N", "uri": "https://ir.zymeworks.com/static-files/0ece631e-035b-4d87-85b8-a4f240768846", "label": "ir.zymeworks.com", "score": 10.0171115674, "published": false}], "size": 2, "hash": "7189b9574a0cb2456b01118d2f7b9054", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbenltZXdvcmtzLXBsYXRmb3JtIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means Zymeworks\u2019 proprietary Azymetric\u2122 [\u2026***\u2026] technology platform, comprised of mutations which enable the efficient formation of [\u2026***\u2026], as described in the Technical Dossier.", "title": "Zymeworks Platform", "size": 35, "id": "zymeworks-platform", "examples": ["Without limiting the foregoing and notwithstanding anything herein to the contrary (except as provided in this Section 2.3 or Section 8.4 below), the licenses granted to Lilly in this Agreement do not include the right to utilize or otherwise exploit the <strong>Zymeworks Platform</strong> to independently develop or modify Antibodies or to modify or improve the <strong>Zymeworks Platform</strong>.", "Section 6.1.1) Zymeworks shall own and retain all rights in the <strong>Zymeworks Platform</strong> Improvements.", "For clarity, all antibody mutations created or introduced by Zymeworks using the <strong>Zymeworks Platform</strong> will comprise improvements thereto and will be owned by Zymeworks, subject to the rights and licenses granted to Lilly hereunder including pursuant to Sections 2.1 and 8.4; provided, however, that the physical embodiment of all Antibodies shall be owned by Lilly, subject to the rights and licenses granted to Zymeworks hereunder, including pursuant to Sections 2.2, 5.3, 11.1.2 and 11.1.", "For clarity, GSK would have the right to use the <strong>Zymeworks Platform</strong> solely for purposes of researching and developing GSK Antibodies to be incorporated in any Product; and researching, developing and commercializing such Products, in each case in accordance with the Licenses and this Agreement.", "For clarity, GSK shall exclusively own GSK Sequence Pairs, GSK Antibodies, the Products and any mutations or modifications to the GSK Sequence Pairs made by GSK alone or jointly with Third Parties; provided that Zymeworks shall retain all rights in and to the <strong>Zymeworks Platform</strong> and any <strong>Zymeworks Platform</strong> Improvements.", "Other than any such Inventions comprising <strong>Zymeworks Platform</strong> Improvements, Inventions created in the exercise of the Licenses solely by GSK or its Affiliates, sublicensees or subcontractors (\u201cGSK Inventions\u201d), together with all Know-How and Intellectual Property rights therein, shall be owned solely by GSK.", "Zymeworks shall not seek to obtain any patent term restoration or supplemental protection certificates or the like or their equivalents of <strong>Zymeworks Platform</strong> Patents in any country in the Territory with respect to Licensed Products.", "GSK would be entitled to credit against the royalties owed by GSK to Zymeworks pursuant to this Section 4.5 up to [\u2026***\u2026]percent ([\u2026***\u2026]%) of any royalties paid by GSK to Third Parties on sales of Products in consideration for licenses under Patent Rights Covering the <strong>Zymeworks Platform</strong> for purposes of manufacturing or commercializing such Product; provided that such credit shall be subject to the limitation set forth in the last sentence of Section 4.5.2.", "Subject to the Licenses expressly granted to GSK hereunder and the other terms and conditions of this Agreement, as between the Parties, Zymeworks shall retain all rights, title and interest in and to the <strong>Zymeworks Platform</strong> and the Zymeworks Intellectual Property.", "Moreover, during such period, Zymeworks will also not apply the <strong>Zymeworks Platform</strong> to antibodies Directed To a Lilly Target Pair other than pursuant to a Research Plan or (b) for internal research pre-approved in writing by Lilly."], "related": [["online-platform", "online platform", "online platform"], ["hosting-platform", "Hosting platform", "Hosting platform"], ["content-platform", "Content Platform", "Content Platform"], ["trading-platform", "Trading Platform", "Trading Platform"], ["program-materials", "Program Materials", "Program Materials"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}